



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/524,313	07/15/2005	David J. Rys	1282-P02956US01	6431
27667	7590	09/03/2010		
HAYES SOLOWAY P.C. 3450 E. SUNRISE DRIVE, SUITE 140 TUCSON, AZ 85718			EXAMINER PURDY, KYLE A	
			ART UNIT	PAPER NUMBER
			1611	
			NOTIFICATION DATE	DELIVERY MODE
			09/03/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

admin@hayes-soloway.com
smckniff@hayes-soloway.com
nsoloway@hayes-soloway.com

Office Action Summary	Application No. 10/524,313	Applicant(s) RYS ET AL.	
	Examiner Kyle Purdy	Art Unit 1611	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 1/25/2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4 and 11-23 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4 and 11-23 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>2 pages (8/24/2010)</u> . | 6) <input type="checkbox"/> Other: _____ |




DETAILED ACTION

Status of Application

1. The Examiner acknowledges receipt of the arguments filed on 1/25/2010.
2. Claims 1-4 and 11-23 are presented for examination on the merits. Claims 5-10 and 24-33 remain withdrawn. The following rejections are made.

Allowable Subject Matter

3. The compositions (85:5:10; EtOH:water:PG) comprising the species depicted below (Table 1 of declaration) are allowable:

Example Number	R ₁	Meta Position Solubility (mg/mL)	Para Position Solubility (mg/mL)
1	-CH ₂ CH ₂ CH ₃	1.9	0.18
2		2.10	0.09
6	-OCH ₂ CH ₃	1.85	0.30
16	-CH ₂ CH ₂ OCH ₃	1.14	0.29
20		1.45	0.21
27	-NO ₂	0.98	0.16
31		0.08	0.03

4. However, as the claims also contain para-substituted compounds (i.e. amido, cyano, halogen) which were not shown to have improved solubility over the meta-substituted compounds and are accordingly rejected below.

5. Moreover, as the species identified by the declaration do not show any specific trend with respect to R₁ para-substituent and solubility, they generic class of compounds cannot be allowed. For example, Applicant shows only one alkyl (propyl) para-substituted compound in their declaration which is sufficient for that particular compounds allowability. However, while the

showing is sufficient for that compound itself to be allowed, the showing is insufficient for the class of alkyl para-substituted compounds to be allowed, absent a showing otherwise, i.e. an expanded solubility profile where the alkyl chain is extended in length.

Response to Applicants' Arguments

6. Applicants arguments filed 1/25/2010 regarding the objection to claim 22 made by the Examiner for an allowable claim as being dependent from a rejected base claim have been fully considered but they are not found persuasive. However, this objection is withdrawn as the overall claim contains non-allowable subject matter.

7. Applicants arguments filed 1/25/2010 regarding the rejection of claims 1-4, 11-21 and 23 made by the Examiner under 35 USC 103(a) over Nitz et al. (WO 99/38508) in view of DeLuca et al. (Pharma. Dosage Forms Vol. 1; 1992) have been fully considered but they are not found persuasive.

8. The rejection of claims 1-4, 11-21 and 23 made by the examiner under 35 USC 103(a) is **MAINTAINED** for the reasons of record in the office action mailed on 02/26/2009.

9. In regards to the 103(a) rejection, Applicant asserts the following:

A) The solubility characteristics of the meta-substituted compounds claim in the application are superior to the corresponding para-substituted compounds, especially in solvent systems customarily used in electrohydrodynamic (EHD) delivery devices for pulmonary administration.

10. In response to assertion A, the Examiner acknowledges that the compounds have improved solubility in an EHD solvent matrix relative to the para-substituted compounds.

Applicant is reminded that the composition comprising the EHD solvent system (85% ethanol,

Art Unit: 1611

10% propylene glycol and 5% water) as set forth in claim 22 has been indicated as allowable subject matter and is currently objected to. With respect to Applicants broader claim to a solvent matrix comprising ethanol, water and propylene glycol, this is still obvious in view of DeLuca. DeLuca is directed to parenteral formulations and carrier vehicles thereof. It's taught that when the compounds to be solvated are substantially non-polar, such as the instant compounds, waters presence in the composition is to be limited, especially if the compound is susceptible to hydrolysis. It's taught that co-solvents such as ethanol and propylene glycol are to be used to improve solubility of the non-polar compound. Thus, in view of DeLuca, one would have been motivated to formulate the instant compounds in a composition comprising water, ethanol and propylene glycol so that the compound was sufficiently solubilized for administration to a subject, wherein the composition had minimal amounts of water. Applicants arguments are not found persuasive.

Maintained Objections and Rejections, of record (claims 1-4, 11-21 and 23) and New
Rejections, of Record (claim 22)
Claim Rejections - 35 USC § 103


11. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

12. Claims 1-4 and 11-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nitz et al. (WO 99/38508; of record) in view of DeLuca et al. (Pharma. Dosage Forms Vol. 1: Parenteral Medications, 1992, 173-175; of record).

13. The claims of the instant application are drawn to a compound having the following structure wherein the species occupying the RI position is propyl. The compound is used in a pharmaceutical composition, in an amount effective to attenuate infectivity of pneumovirus. The composition further comprises at least one supplemental active agent such as interferons, immunoglobins, antibiotics, etc. The composition may comprise ethanol from at least 50% to at least 90% of the composition in addition to propylene glycol, and water. Preferably however, the composition comprises 85% ethanol, about 10% propylene glycol and less than 5% water.

14. The teaching of Nitz et al. ('508) is drawn to compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases. The compounds use to treat pneumovirus have the following structure



The species which may occupy the X, R, R2 and R3 are identical to those of the instant application in that X may be -C=N, R may be propyl, R2 is hydroxyl, and R3 is 5-methyl-1-tetrazolyl (see page 4, line 15 - page 5, line 5 and Example 10). The difference between '508 and the instant application, R and R~ respectively, is the position of the substituent on the benzene ring. The substituent of '508 is in the para position whereas the instant applications substituent is in the meta position. Typically structural homologs, either isomers (i.e. cis vs.

Art Unit: 1611

trans) or positional isomers (i.e. meta vs. para), often have similar pharmacological properties. With that stated chemists of ordinary skill would contemplate making slight variations of a known compound in order to obtain compounds with better and improved properties. The compounds of the prior art would motivate such routine organic synthesis and optimization, leading to the instantly claimed compounds which possess efficacy as inhibitors of pneumovirus replication. See *In re Deuel*, 51 F.3d 1552, 1558, 34 USPQ2d 1210, 1214. The teaching of '508 also stipulates for the inclusion of supplemental active agents such as interferons, antibiotics, and immunoglobins.

15. The reference teaches that the carrier solvent of the pharmaceutically active compound can consist of any "pharmaceutically acceptable carrier medium" meaning that the carrier includes any and all solvents. This would necessarily encompass and motivate the inclusion of ethanol, propylene glycol and water. Still, however, '508 specifically fails to include ethanol, propylene glycol, and water in the pharmaceutical preparation.

16. The teaching of DeLuca et al ('DeLuca) is drawn to parenteral formulations and useful carrier vehicles thereof. On page 175, Section B, it is noted that most parenteral products are aqueous solutions. However, inclusion of water may have to be limited if the active compound is susceptible to chemical degradation (i.e. hydrolysis, racemization, etc.). It is stated that for non-polar substances possessing limited solubility in water, it is necessary to use co-solvents such as ethanol and propylene glycol. Although DeLuca does not specifically teach adding the ingredients together in the amounts claimed. The amount of a specific ingredient in a composition is a result effective parameter that any person of ordinary skill in the art would

Art Unit: 1611

desire to optimize. The instantly claimed percentages of said solvents, as described above, could readily be attained by routine experimentation and optimization.

17. Thus, it would have been obvious to one of ordinary skill in the art, at the time the invention was made, to combine the teachings of '508 and DeLuca because in doing so one would create a pharmaceutically active formulation suitable for safe administration to a patient. The instantly claimed compound are obvious as they are structural isomers of reference '508 and one of ordinary skill in the art would be motivated to make such modifications with the expectation that the compounds and compositions thereof would possess identical pharmacological properties as those taught by the reference. Moreover, the use of water, ethanol, and/or propylene glycol as a carrier medium would be motivated by '508 statements that all pharmacologically acceptable carrier mediums can be used to carry the drugs. This motivates one to look to the prior art of drug formulations where is found that solvents such as water, ethanol and propylene glycol are commonly used as a carrier medium. Furthermore, the specifically claimed percentages of said carrier do not qualify as patentable subject matter, as these values could found via routine experimentation and optimization. Therefore, it would have been obvious to a person of ordinary skill in the art to combine the teachings of '508 with that of DeLuca with a reasonable expectation of success.

Conclusion

18. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kyle A. Purdy whose telephone number is 571-270-3504. The examiner can normally be reached from 9AM to 5PM.

Art Unit: 1611

19. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sharmila Landau, can be reached on 571-272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

20. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*/Kyle Purdy/
Examiner, Art Unit 1611
August 25, 2010*

*/Sharmila Gollamudi Landau/
Supervisory Patent Examiner, Art Unit 1611*